Education
About Us
Working with TipRanks
Follow Us
Gt Biopharma, Inc. (GTBP)
:GTBP
GTBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.72 - $10.66
Previous CloseN/A
Volume15.05K
Average Volume (3M)34.89K
Market Cap
$5.86M
Enterprise Value$2.77M
Total Cash (Recent Filing)$840.00K
Total Debt (Recent Filing)$2.60M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 19, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.02
Shares Outstanding2,536,397
10 Day Avg. Volume20,713
30 Day Avg. Volume34,892
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$11.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Ownership Overview
―
Insiders
0.98% Mutual Funds
0.07% Other Institutional Investors
98.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GTBP FAQ
What was Gt Biopharma, Inc.’s price range in the past 12 months?
Gt Biopharma, Inc. lowest stock price was $1.72 and its highest was $10.66 in the past 12 months.
What is Gt Biopharma, Inc.’s market cap?
Gt Biopharma, Inc.’s market cap is $5.86M.
When is Gt Biopharma, Inc.’s upcoming earnings report date?
Gt Biopharma, Inc.’s upcoming earnings report date is May 19, 2025 which is in 36 days.
How were Gt Biopharma, Inc.’s earnings last quarter?
Gt Biopharma, Inc. released its earnings results on Feb 21, 2025. The company reported -$1.67 earnings per share for the quarter, missing the consensus estimate of -$1.55 by -$0.12.
Is Gt Biopharma, Inc. overvalued?
According to Wall Street analysts Gt Biopharma, Inc.’s price is currently Undervalued.
Does Gt Biopharma, Inc. pay dividends?
Gt Biopharma, Inc. does not currently pay dividends.
What is Gt Biopharma, Inc.’s EPS estimate?
Gt Biopharma, Inc.’s EPS estimate is -0.64.
How many shares outstanding does Gt Biopharma, Inc. have?
Gt Biopharma, Inc. has 2,536,397 shares outstanding.
What happened to Gt Biopharma, Inc.’s price movement after its last earnings report?
Gt Biopharma, Inc. reported an EPS of -$1.67 in its last earnings report, missing expectations of -$1.55. Following the earnings report the stock price went up 0.939%.
Which hedge fund is a major shareholder of Gt Biopharma, Inc.?
Currently, no hedge funds are holding shares in GTBP
---
Company Description
Gt Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
---
GTBP Stock 12 Month Forecast
Average Price Target
$11.00
▲(376.19% Upside)
Technical Analysis
Celldex
―
Immutep
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering GTBP
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-14.65%
reiterated a buy rating 2 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.65% per trade.
---